Peripheral blood mononuclear cell therapy in PAD patients with intermittent claudication randamized trial

Peripheral blood mononuclear cell therapy in PAD patients with intermittent claudication randamized trial - PB-MNC therapy (PERTINENT) trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000330

Enrollment

Registered

2006-02-15

Start date

2006-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ASO/Buerger disease

Interventions

PB-MNC implantation Saline

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: PAD patients presenting with severe IC resistant to conventional therapies

Exclusion criteria

Exclusion criteria: Patients with malignant diseases, severe diabetic retinopathy, or severe renal failure.

Design outcomes

Primary

Measure	Time frame
Maximum walking distance, Pain-free walking distance, Recovery time of lower leg BP after exercise, ABPI at 6 months after treatment as compared with those before treatment	—

Secondary

Measure	Time frame
Laser doppler image, Scintigraphy, MRI, Angiography, QOL estimation	—

Countries

Japan

Contacts

Public ContactTohru Minamino

Chiba University Graduate School of Medicine Department of Cardiovascular Science and Medicine

t_minamino@yahoo.co.jp043-226-2964

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026